Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Sep 29, 2008

Response Genetics Creates Sales Strategy for Its ResponseDX Tests

  • Response Genetics is enhancing its sales strategy for its prognostic tests for colon and lung cancers. It has formed an in-house sales team and exclusively signed on NeoGenomics as an authorized national clinical reference laboratory.

    ResponseDX: Colon™ and ResponseDX: Lung™ are designed to help with treatment decisions for patients with non-small-cell lung cancer and colorectal cancer. These PCR-based panels include three key genes: ERCC1, TS and EGFR. The tests also include the analysis of K-ras gene mutations, which is a strong predictor of nonresponse and no benefit from the epidermal growth factor receptor inhibitors.

    Response Genetics was unavailable to comment on the current uptake of the tests. In March, the firm made ResponseDX: Colon and ResponseDX: Lung available to select medical institutions and practice groups through its CLIA-registered laboratory.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »